Tvardi Financial Statements From 2010 to 2025

TVRD Stock   4.00  0.02  0.50%   
Tvardi Therapeutics,'s financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Tvardi Therapeutics,'s valuation are provided below:
Market Capitalization
242.3 M
Earnings Share
(2.25)
There are over one hundred nineteen available fundamental trend indicators for Tvardi Therapeutics,, which can be analyzed over time and compared to other ratios. Investors should ensure to double-check all of Tvardi Therapeutics,'s current performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. The current year's Enterprise Value is expected to grow to about 14.7 M, whereas Market Cap is forecasted to decline to about 7.1 M.

Tvardi Therapeutics, Total Revenue

6.78 Million

Check Tvardi Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tvardi Therapeutics,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 182.4 K, Total Revenue of 6.8 M or Other Operating Expenses of 92.3 M, as well as many indicators such as Price To Sales Ratio of 0.74, Dividend Yield of 0.0 or Days Sales Outstanding of 241. Tvardi financial statements analysis is a perfect complement when working with Tvardi Therapeutics, Valuation or Volatility modules.
  
Build AI portfolio with Tvardi Stock
Check out the analysis of Tvardi Therapeutics, Correlation against competitors.
For information on how to trade Tvardi Stock refer to our How to Trade Tvardi Stock guide.

Tvardi Therapeutics, Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets41.6 M43.8 M211.7 M
Slightly volatile
Short and Long Term Debt Total46.7 M44.4 M9.7 M
Slightly volatile
Total Current Liabilities7.6 MM15 M
Slightly volatile
Property Plant And Equipment Net323.2 K340.2 K3.8 M
Slightly volatile
Accounts Payable2.6 M1.4 M4.2 M
Slightly volatile
Cash28 M37.9 M29.5 M
Slightly volatile
Non Current Assets Total720.8 K758.7 K57.1 M
Slightly volatile
Cash And Short Term Investments72.4 M37.9 M145.9 M
Slightly volatile
Net Receivables3.6 M4.5 M2.5 M
Slightly volatile
Common Stock Shares Outstanding1.4 M1.5 M2.4 M
Slightly volatile
Short Term Investments74.8 M44.1 M124.1 M
Slightly volatile
Liabilities And Stockholders Equity41.6 M43.8 M211.7 M
Slightly volatile
Non Current Liabilities Total48.8 M44.4 M19.2 M
Slightly volatile
Other Stockholder Equity788.6 M751 M581.4 M
Pretty Stable
Total Liabilities59.2 M48.4 M34.4 M
Slightly volatile
Total Current Assets77.2 M43.8 M156.9 M
Slightly volatile
Short Term Debt79.5 K83.7 K1.4 M
Slightly volatile
Common Stock4.8 KK40.7 K
Slightly volatile
Inventory1.4 M810 K2.2 M
Slightly volatile
Capital Lease Obligations327.2 K331.2 K429.8 K
Slightly volatile
Property Plant And Equipment Gross335.2 K340.2 K439.6 K
Slightly volatile
Capital Stock15.2 K17.1 K18.6 K
Slightly volatile
Net Working Capital25.1 M20.6 M36.6 M
Slightly volatile
Intangible Assets383.6 K403.2 K492.4 K
Slightly volatile

Tvardi Therapeutics, Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization182.4 K192 K938.9 K
Slightly volatile
Total Revenue6.8 M7.1 M99.1 M
Slightly volatile
Other Operating Expenses92.3 M62.9 M122.9 M
Slightly volatile
Research Development31.1 M32.8 M95.7 M
Slightly volatile
Total Operating Expenses89.5 M62.1 M121 M
Slightly volatile
Gross ProfitM6.3 M19.9 M
Slightly volatile
Cost Of Revenue771.4 K812 K2.1 M
Slightly volatile
Net Interest Income1.1 M1.5 M773.7 K
Slightly volatile
Interest Income1.1 M1.5 M776.3 K
Slightly volatile
Selling General AdministrativeM3.2 M2.8 M
Slightly volatile
Reconciled Depreciation99 K109.2 K88 K
Slightly volatile

Tvardi Therapeutics, Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow40.7 M52.2 M25.5 M
Slightly volatile
Depreciation182.4 K192 K829.6 K
Slightly volatile
Capital Expenditures849 KM512.4 K
Slightly volatile
End Period Cash Flow28 M37.9 M29.5 M
Slightly volatile
Stock Based Compensation308 K361.1 K261.3 K
Slightly volatile
Issuance Of Capital Stock2.4 K1.8 K3.6 K
Slightly volatile
Other Cashflows From Investing Activities92.8 M104.4 M113.8 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.741.04420.3682
Slightly volatile
Days Sales Outstanding24123041.2261
Slightly volatile
Stock Based Compensation To Revenue0.00830.01350.0071
Slightly volatile
Capex To Depreciation5.154.91.2433
Slightly volatile
Inventory Turnover0.60.810.6519
Slightly volatile
Days Of Inventory On Hand556465570
Slightly volatile
Payables Turnover0.540.56620.7209
Slightly volatile
Sales General And Administrative To Revenue0.07940.120.0737
Slightly volatile
Research And Ddevelopement To Revenue4.824.58951.4354
Slightly volatile
Capex To Revenue0.150.14660.0276
Slightly volatile
Cash Per Share23.6824.9212105
Slightly volatile
Days Payables Outstanding5986451.1 K
Slightly volatile
Intangibles To Total Assets0.01120.01490.0119
Slightly volatile
Current Ratio10.9311.03410.3861
Pretty Stable
Receivables Turnover1.511.587847.3514
Slightly volatile
Capex Per Share0.720.68770.2881
Slightly volatile
Revenue Per Share4.464.692672.527
Slightly volatile
Interest Debt Per Share36.5434.79567.3933
Slightly volatile
Debt To Assets1.061.01420.1481
Slightly volatile
Graham Number132148162
Slightly volatile
Operating Cycle666634131
Slightly volatile
Days Of Payables Outstanding5986451.1 K
Slightly volatile
Ebt Per Ebit1.231.27761.3229
Slightly volatile
Long Term Debt To Capitalization0.91.01.0946
Slightly volatile
Quick Ratio10.8610.807410.3584
Slightly volatile
Net Income Per E B T1.140.99441.078
Pretty Stable
Cash Ratio10.029.54253.1995
Slightly volatile
Days Of Inventory Outstanding556465570
Slightly volatile
Days Of Sales Outstanding24123041.2261
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.171.0631
Pretty Stable
Fixed Asset Turnover35.8649.9233.058
Slightly volatile
Debt Ratio1.061.01420.1481
Slightly volatile
Price Sales Ratio0.741.04420.3682
Slightly volatile
Asset Turnover0.150.16280.4744
Pretty Stable
Gross Profit Margin0.910.88620.9063
Slightly volatile

Tvardi Therapeutics, Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap7.1 M7.5 M11.5 M
Slightly volatile

Tvardi Fundamental Market Drivers

About Tvardi Therapeutics, Financial Statements

Tvardi Therapeutics, stakeholders use historical fundamental indicators, such as Tvardi Therapeutics,'s revenue or net income, to determine how well the company is positioned to perform in the future. Although Tvardi Therapeutics, investors may analyze each financial statement separately, they are all interrelated. For example, changes in Tvardi Therapeutics,'s assets and liabilities are reflected in the revenues and expenses on Tvardi Therapeutics,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Tvardi Therapeutics,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Revenue7.1 M6.8 M
Cost Of Revenue812 K771.4 K
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.12  0.08 
Research And Ddevelopement To Revenue 4.59  4.82 
Capex To Revenue 0.15  0.15 
Revenue Per Share 4.69  4.46 
Ebit Per Revenue(7.82)(7.42)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Tvardi Therapeutics, is a strong investment it is important to analyze Tvardi Therapeutics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tvardi Therapeutics,'s future performance. For an informed investment choice regarding Tvardi Stock, refer to the following important reports:
Check out the analysis of Tvardi Therapeutics, Correlation against competitors.
For information on how to trade Tvardi Stock refer to our How to Trade Tvardi Stock guide.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tvardi Therapeutics,. If investors know Tvardi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tvardi Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.25)
The market value of Tvardi Therapeutics, is measured differently than its book value, which is the value of Tvardi that is recorded on the company's balance sheet. Investors also form their own opinion of Tvardi Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Tvardi Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tvardi Therapeutics,'s market value can be influenced by many factors that don't directly affect Tvardi Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tvardi Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Tvardi Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tvardi Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.